Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.Complete coverage includes: Improvements in vector developments Delivery systems Cell therapy Small nucleic acid therapeutics, including RNAi Clinical trials and animal models Clinical protocols Pre-clinical animal and in vitro studies to assess the safety of gene and cell therapy products used to support clinical applications Clinical trials including those in which the results are confirmatory or negative Topical issues related to the commercial development of gene and cell therapy productsHuman Gene Therapy was voted one of the most influential journals in Biology and Medicine over the last 100 years by the Biomedical & Life Sciences Division of the Special Libraries Association.Human Gene Therapy, HGT Methods, and HGT Clinical Development are under the editorial leadership of Editor-in-Chief Terence R. Flotte, MD, University of Massachusetts Medical School; Deput Editors Europe Nathalie Cartier, MD, INSERM, and Thierry VandenDriessche, PhD, Free University of Brussels (VUB); Deputy Editors U.S. Barry J. Byrne, MD, PhD, Powell Gene Therapy Center, University of Florida, College of Medicine and Mark A. Kay, MD, PhD, Stanford University School of Medicine; Human Gene Therapy Editor Guangping Gao, PhD, University of Massachusetts Medical School; Methods Editor Hildegard Büning, PhD, Hannover Medical School; Clinical Development Editor James M. Wilson, MD, PhD, University of Pennsylvania School of Medicine, Gene Therapy Program; and other leading investigators. View the entire editorial board.Audience: Geneticists, medical geneticists, molecular biologists, virologists, experimental researchers, and experimental medicine specialists, among others.Human Gene Therapy and HGT Methods provide “Instant Online” publication 72 hours after acceptance

《人類基因治療》是一本涵蓋基因治療各個方面的多學科雜志。該雜志通過提供最新的研究和技術突破，對DNA、RNA和細胞療法進行了深入報道。人類基因治療為科學和臨床信息提供了一個中心論壇，包括倫理、法律、監管、社會和商業問題，使治療程序的進步和進步能夠改善患者的結果，并最終治愈疾病。該期刊分為三個部分。人類基因療法是其旗艦，每年出版12期。《HGT Methods》是一本雙月刊，主要研究基因治療在產品檢測和開發中的應用。HGT臨床發展是一份季刊，作為發布與細胞和基因治療產品的監管審查和商業開發相關的數據的場所。完整的覆蓋范圍包括:向量發展的改善運載系統細胞療法小型核酸療法，包括RNAi臨床試驗和動物模型臨床協議臨床前動物和體外研究評估用于支持臨床應用的基因和細胞治療產品的安全性臨床試驗，包括結果證實性或陰性的臨床試驗與基因和細胞治療產品的商業開發相關的熱點問題《人類基因療法》被美國特殊圖書館協會生物醫學與生命科學部評選為近100年來生物學和醫學領域最具影響力的期刊之一。人類基因治療、HGT方法和HGT臨床開發由麻省大學醫學院醫學博士特倫斯·r·弗洛特主編;Deput歐洲編輯Nathalie Cartier，醫學博士，INSERM，和Thierry VandenDriessche，博士，布魯塞爾自由大學(VUB);美國佛羅里達大學醫學院鮑威爾基因治療中心副編輯Barry J. Byrne醫學博士，斯坦福大學醫學院Mark A. Kay醫學博士;人類基因治療編輯高廣平，麻省大學醫學院博士;方法編輯Hildegard Buning，博士，漢諾威醫學院;臨床發展編輯James M. Wilson，醫學博士，賓夕法尼亞大學醫學院，基因治療項目;以及其他主要調查人員。查看整個編輯委員會。觀眾:遺傳學家、醫學遺傳學家、分子生物學家、病毒學家、實驗研究人員、實驗醫學專家等。人類基因治療和HGT方法提供“即時在線”出版后72小時接受